Feature

Referral system aims to slash axial spondyloarthritis diagnostic delay


 

Community back pain clinics

Raja Rampersaud, MD, a spine surgeon at UHN, developed the first model – a community clinic that triages and treats people with low back pain. Primary care providers refer into the clinics, and advanced practice clinicians work with patients to create care plans. These might include low-level medical therapy, exercise, and other self-management techniques.

Ms. Passalent and her team partnered with these clinics in a pilot project to identify axSpA patients. The team provided clinician education and referral criteria for patients. These include back pain of more than 3 months’ duration in patients younger than 50 years who have other signs of inflammatory back pain. Primary care providers can refer such patients to a secondary screening program, run by an advanced care clinician, that further refines the diagnosis.

The clinic work-up includes the following:

  • History, involving a description of back pain, peripheral joint involvement, and extra-articular manifestations.
  • Physical exam looking at spinal mobility and vital signs, as well as tender/swollen joints, enthesitis, and dactylitis.
  • Investigations that include pelvis and lateral lumbar and cervical spine radiographs, HLA-B27 testing, and measurements of C-­reactive protein and erythrocyte sedimentation rate.

For those who don’t tick the axSpA boxes, the practitioner provides education on self-management, basic nonpharmacologic interventions, exercise guidance, and referrals back into primary care for their therapy.

But those who screen positive receive a direct rheumatology referral. This is an especially important component of the program because, like the United States, Canada has a chronic shortage of rheumatologists. However, in Canada there can be even greater distances than in the United States between a patient’s town and the closest rheumatology office. The back pain screening clinic reduced waiting time from up to 2 years to around 3 weeks – a notable accomplishment in a country with only about 500 rheumatologists – less than 1 per 75,000 residents.

First data

Ms. Passalent and the team presented their initial data from this model at recent annual meetings of the Canadian Rheumatology Association and the American College of Rheumatology (Arthritis Rheumatol. 2018;70[suppl 10]:Abstract 661).

During the first 3 years of the project, 410 patients were seen. Time from primary care referral to the secondary clinic appointment was roughly 22 days. These patients were young, with a mean age of about 37 years, and had experienced back pain for an average of 7 years. About 14% were positive for HLA-B27, but that characteristic signal actually performed poorly as an independent axSpA screen. It was highly specific (94%) but not very sensitive (28%), with a 71% positive and negative predictive value.

Assessment by the advanced care provider, on the other hand, had 90% specificity and 68% sensitivity. The negative and positive predictive values were 80% and 84%, respectively.

Among those who had a rheumatology consult, 18% received an axSpA diagnosis.

“We were very pleased to be able to decrease the time to diagnosis, from 9 years to 6 or 7,” Ms. Passalent said. “It’s still a long time, but you have to keep in mind this program is just getting started.”

Recommended Reading

Algorithm proposes approach for managing TNF inhibitor–induced psoriasis
MDedge Internal Medicine
Back pain criteria perform well in patients with active axial psoriatic arthritis
MDedge Internal Medicine
CRP predicts anti-TNF response in ankylosing spondylitis
MDedge Internal Medicine
Back pain persists in one in five patients
MDedge Internal Medicine
Anti-TNFs slow SIJ damage in early axial spondyloarthritis
MDedge Internal Medicine
TNF inhibitors improve BMD in ankylosing spondylitis
MDedge Internal Medicine
Venous thromboembolism risk elevated in ankylosing spondylitis patients
MDedge Internal Medicine
Recent trials advance axial spondyloarthritis therapy
MDedge Internal Medicine
Biologics boost work outcomes in axial spondyloarthritis
MDedge Internal Medicine
Cimzia becomes first FDA-approved treatment for nonradiographic axial spondyloarthritis
MDedge Internal Medicine